4 results
•To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between sacituzumab govitecan (SG) versus treatment of physician*s choice (TPC)Secondary Objectives:•To compare overall survival (OS) between the 2…
Primary Objective:- To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between sacituzumab govitecan (SG) and pembrolizumab versus treatment of physician*s choice (TPC) and pembrolizumab. Secondary…
The aim of the POLO study is to evaluate pharmacokinetics and safety of a single-dose of dolutegravir in patients with severe hepatic impairment (Child-Pugh score * 10) and compare these to matched controls.
To compare the overall survival (OS) of sacituzumab govitecan (SG) versus docetaxel.